• DLBCL Specialist

Prof. Younes has spent more than 25 years caring for patients with lymphoma and lead numerous clinical trials that advanced the field. His research resulted in the US Food and Drug Administration approval of two novel agents for patients with Hodgkin lymphoma, including the first targeted drug for the treatment of Hodgkin lymphoma in more than three decades (brentuximab vedotin), and the approval of the first immune checkpoint inhibitor for lymphoma (nivolumab).